PE20131338A1 - Composiciones farmaceuticas y metodos de tratamiento - Google Patents
Composiciones farmaceuticas y metodos de tratamientoInfo
- Publication number
- PE20131338A1 PE20131338A1 PE2013000073A PE2013000073A PE20131338A1 PE 20131338 A1 PE20131338 A1 PE 20131338A1 PE 2013000073 A PE2013000073 A PE 2013000073A PE 2013000073 A PE2013000073 A PE 2013000073A PE 20131338 A1 PE20131338 A1 PE 20131338A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- pharmaceutical compositions
- methods
- antibody
- nos
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001632 homeopathic effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE TIENE UNA FORMULACION ACTIVADA Y POTENCIADA DE UN ANTICUERPO PARA EL RECEPTOR CANABINOIDE HUMANO 1 (CB1) EN SU TOTALIDAD CONSTA DE LA SECUENCIA PROPORCIONADA EN SEQ ID NOS:1 Y EL FRAGMENTO DE DICHO RECEPTOR TIENE LA SECUENCIA EN SEQ ID NOS: 2-15. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UNA FORMA POTENCIADA DE UN ANTICUERPO A LA PROTEINA S-100 QUE TIENE SECUENCIA ID NO: 16. DICHA COMPOSICION ESTA EN FORMA DE UNA MEZCLA DE DILUCIONES HOMEOPATICAS C12, C30 Y C200 IMPREGNADAS EN UN PORTADOR SOLIDO. LA PRESENTE INVENCION PROPORCIONA METODOS PARA EL TRATAMIENTO DE LA OBESIDAD, LOS TRASTORNOS METABOLICOS RELACIONADOS Y ABUSO DE SUSTANCIAS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010129289/15A RU2552221C2 (ru) | 2010-07-15 | 2010-07-15 | Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств |
RU2010130350/15A RU2533224C2 (ru) | 2010-07-21 | 2010-07-21 | Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения |
RU2011122407A RU2610438C2 (ru) | 2011-06-02 | 2011-06-02 | Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20131338A1 true PE20131338A1 (es) | 2013-11-18 |
Family
ID=44899164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000073A PE20131338A1 (es) | 2010-07-15 | 2011-07-15 | Composiciones farmaceuticas y metodos de tratamiento |
Country Status (29)
Country | Link |
---|---|
US (1) | US8865163B2 (es) |
EP (1) | EP2593477A2 (es) |
JP (1) | JP2013535436A (es) |
KR (1) | KR20140012009A (es) |
CN (1) | CN103124742A (es) |
AR (1) | AR082246A1 (es) |
AU (1) | AU2011278040B2 (es) |
BR (1) | BR112013000841A2 (es) |
CA (1) | CA2805091A1 (es) |
CL (1) | CL2013000098A1 (es) |
CZ (1) | CZ2013104A3 (es) |
DE (1) | DE112011102349T5 (es) |
DK (1) | DK201370078A (es) |
EA (1) | EA029400B1 (es) |
EE (1) | EE05760B1 (es) |
ES (1) | ES2542042R1 (es) |
FI (1) | FI20135146L (es) |
FR (1) | FR2962653A1 (es) |
GB (1) | GB2496076B (es) |
IT (1) | ITTO20110641A1 (es) |
LT (1) | LT5987B (es) |
MX (1) | MX361778B (es) |
MY (1) | MY158183A (es) |
NO (1) | NO20130219A1 (es) |
NZ (1) | NZ606768A (es) |
PE (1) | PE20131338A1 (es) |
SE (1) | SE1350179A1 (es) |
SG (1) | SG187037A1 (es) |
WO (1) | WO2012007847A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
AU2011287288A1 (en) | 2010-07-15 | 2013-03-07 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
NZ606767A (en) | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
GB2495885B (en) * | 2010-07-15 | 2017-11-22 | Iliich Epshtein Oleg | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
MX2013000807A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion. |
CZ2013124A3 (cs) * | 2010-07-21 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby diabetu a metabolických chorob |
DE112011102412T5 (de) * | 2010-07-21 | 2013-07-04 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden |
WO2012010974A2 (en) * | 2010-07-21 | 2012-01-26 | Oleg Lliich Epshtein | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
AU2011287292B2 (en) * | 2010-08-06 | 2017-02-02 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
RU2013111961A (ru) * | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
RU2013111962A (ru) * | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
MA39708A (fr) * | 2014-03-27 | 2021-03-31 | Bird Rock Bio Inc | Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain |
CN104524568B (zh) * | 2015-01-08 | 2018-04-20 | 中国人民解放军第二军医大学 | 一种治疗肥胖症的药物组合物及其应用 |
BR112018006633A2 (pt) * | 2015-09-30 | 2018-10-23 | Bird Rock Bio Inc | anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
EA000885B1 (ru) | 1996-02-12 | 2000-06-26 | Олег Ильич ЭПШТЕЙН | Лекарственное средство и способ медикаментозного воздействия на организм |
US5849528A (en) | 1997-08-21 | 1998-12-15 | Incyte Pharmaceuticals, Inc.. | Polynucleotides encoding a human S100 protein |
RU2156621C1 (ru) | 1999-03-04 | 2000-09-27 | Эпштейн Олег Ильич | Нейротропное лекарственное средство |
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
RU2209084C1 (ru) * | 2001-12-26 | 2003-07-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения депрессивных расстройств |
RU2201255C1 (ru) | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
TWI345470B (en) | 2003-03-14 | 2011-07-21 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
US20050100513A1 (en) * | 2003-11-10 | 2005-05-12 | Watkins Mary B. | Homeopathic method and system for treating nicotine addiction |
EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
RU2437678C2 (ru) | 2006-06-06 | 2011-12-27 | Олег Ильич Эпштейн | Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения |
EP2395021A1 (en) * | 2006-06-06 | 2011-12-14 | Oleg Iliich Epshtein | Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
RU2438707C2 (ru) * | 2006-06-06 | 2012-01-10 | Олег Ильич Эпштейн | Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе |
PE20080926A1 (es) * | 2006-10-23 | 2008-07-19 | Lilly Co Eli | Compuestos cb1 |
EP1985295A1 (en) * | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders |
JP2010132631A (ja) * | 2008-11-04 | 2010-06-17 | Bizen Chemical Co Ltd | カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物 |
AU2011287288A1 (en) * | 2010-07-15 | 2013-03-07 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
BR112013000842A2 (pt) | 2010-07-15 | 2016-06-07 | Oleg Lliich Epshtein | composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa. |
DE112011102409T5 (de) | 2010-07-21 | 2013-07-04 | Oleg Iliich Epshtein | Verfahren zur Behandlung der Alzheimer-Krankheit |
FR2962914A1 (fr) | 2010-07-21 | 2012-01-27 | Oleg Iliich Epshtein | Composition pharmaceutique destinee a etre utilisee dans un procede pour traiter les maladies organiques du systeme nerveux, le syndrome psycho-organique et l'encephalopathie |
WO2012010974A2 (en) | 2010-07-21 | 2012-01-26 | Oleg Lliich Epshtein | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
CZ2013124A3 (cs) | 2010-07-21 | 2013-06-12 | Iliich Epshtein@Oleg | Kombinovaná farmaceutická kompozice a zpusoby lécby diabetu a metabolických chorob |
MX2013000807A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion. |
-
2011
- 2011-07-15 CA CA2805091A patent/CA2805091A1/en not_active Abandoned
- 2011-07-15 GB GB1302653.9A patent/GB2496076B/en not_active Expired - Fee Related
- 2011-07-15 EE EEP201300005A patent/EE05760B1/et not_active IP Right Cessation
- 2011-07-15 CN CN2011800442270A patent/CN103124742A/zh active Pending
- 2011-07-15 EA EA201300133A patent/EA029400B1/ru not_active IP Right Cessation
- 2011-07-15 IT IT000641A patent/ITTO20110641A1/it unknown
- 2011-07-15 PE PE2013000073A patent/PE20131338A1/es not_active Application Discontinuation
- 2011-07-15 AU AU2011278040A patent/AU2011278040B2/en not_active Ceased
- 2011-07-15 ES ES201390003A patent/ES2542042R1/es active Pending
- 2011-07-15 CZ CZ20130104A patent/CZ2013104A3/cs unknown
- 2011-07-15 DE DE112011102349T patent/DE112011102349T5/de not_active Ceased
- 2011-07-15 US US13/135,893 patent/US8865163B2/en not_active Expired - Fee Related
- 2011-07-15 FR FR1156473A patent/FR2962653A1/fr not_active Withdrawn
- 2011-07-15 KR KR1020137003750A patent/KR20140012009A/ko not_active Application Discontinuation
- 2011-07-15 JP JP2013519178A patent/JP2013535436A/ja active Pending
- 2011-07-15 EP EP11788222.5A patent/EP2593477A2/en not_active Ceased
- 2011-07-15 WO PCT/IB2011/002404 patent/WO2012007847A2/en active Application Filing
- 2011-07-15 SG SG2013002316A patent/SG187037A1/en unknown
- 2011-07-15 BR BR112013000841A patent/BR112013000841A2/pt not_active IP Right Cessation
- 2011-07-15 MX MX2013000545A patent/MX361778B/es active IP Right Grant
- 2011-07-15 SE SE1350179A patent/SE1350179A1/sv unknown
- 2011-07-15 NZ NZ606768A patent/NZ606768A/en not_active IP Right Cessation
- 2011-07-15 MY MYPI2013000110A patent/MY158183A/en unknown
- 2011-07-18 AR ARP110102576A patent/AR082246A1/es unknown
-
2013
- 2013-01-10 CL CL2013000098A patent/CL2013000098A1/es unknown
- 2013-02-08 NO NO20130219A patent/NO20130219A1/no not_active Application Discontinuation
- 2013-02-14 DK DKPA201370078A patent/DK201370078A/da not_active Application Discontinuation
- 2013-02-14 LT LT2013015A patent/LT5987B/lt not_active IP Right Cessation
- 2013-02-15 FI FI20135146A patent/FI20135146L/fi not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20131338A1 (es) | Composiciones farmaceuticas y metodos de tratamiento | |
PH12017502013A1 (en) | Anti-ox40 antibodies and methods of use thereof | |
MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
MX2020013062A (es) | Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso. | |
CL2012001304A1 (es) | Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. | |
GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
MX2018014456A (es) | Anticuerpos contra alfa-sinucleina y sus usos. | |
CO6551683A2 (es) | Tratamiento para trastornos gastrointestinales | |
HN2008000878A (es) | Anticuerpos anti mn y metodos para su utilizacion | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
CR11849A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad | |
CL2008000348A1 (es) | Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis. | |
AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
GB2505857A (en) | Vaccine adjuvant composition comprising inulin particles | |
CL2013001754A1 (es) | Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias. | |
EA201071126A1 (ru) | Антагонисты рецепторов глюкагона | |
CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
AR075223A1 (es) | Anticuerpos monoclonales anti-trkb agonistas | |
AR082247A1 (es) | Un metodo para incrementar los efectos de una forma activada potenciada de un anticuerpo | |
GT201300058A (es) | Composiciones de anticuerpos anti-vegfr-3 | |
EA201201528A1 (ru) | Комбинация ингибиторов ксантиноксидазы и антагонистов рецепторов ангиотензина-ii и ее применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |